HFA
OCUL icon

Harbert Fund Advisors’s Ocular Therapeutix OCUL Stock Holding History

Harbert Fund Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$585K – 7
2025
Q3 		$585K Buy
+50,000
New +$598K 3.81% 6

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbert Fund Advisors's OCUL Position: Q4 2025 in Review

Harbert Fund Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 50,000 shares — an estimated $585K sold.

Harbert Fund Advisors first reported a position in OCUL in Q3 2025 and held it in 1 quarter. The position peaked at $585K in Q3 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Harbert Fund Advisors reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
  • Harbert Fund Advisors sold 50,000 Ocular Therapeutix shares in Q4 2025, an estimated $585K.
  • Harbert Fund Advisors first reported a position in Ocular Therapeutix in Q3 2025 and held it in 1 quarter.
  • Harbert Fund Advisors's Ocular Therapeutix position peaked at $585K in Q3 2025.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Harbert Fund Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.